Global TradFi & Macroeconomics

Focus on price action and volatility across stocks, bonds, forex, commodities, and major indices. Analyze macro indicators like interest rates, inflation, employment, and policy expectations to decode global liquidity shifts, risk sentiment, and cross-market correlations.
All
Stocks
Metals
Indices
Forex
Commodities

Gate will implement a 10-for-1 reverse stock split for NXXT (NextNRG, Inc.) on September 14, and the cost basis will be adjusted proportionally.

Gate News reports that, according to an official announcement from NextNRG, NXXT (NextNRG, Inc.) will undergo a reverse stock split in the near future. The Gate platform will support and cooperate with the implementation of the reverse split at a ratio of 10:1. According to the arrangement, trading of NXXT shares will be suspended at 14:00 (UTC+8) on September 14, 2026, and the platform will cancel all unfilled Maker orders. The system will automatically complete the reverse split at the applica
NXXT+858.75%
GateNews·09-11 04:20
Gate will implement a 10-for-1 reverse stock split for NXXT (NextNRG, Inc.) on September 14, and the cost basis will be adjusted proportionally.

What is the probability that the Fed will raise interest rates at its Sept. meeting? From PPI to CPI, how are event markets pricing it?

The FED will hold an FOMC meeting from September 15 to 16, and the market debate over whether to raise Interest Rates has reached a fever pitch. The starting point for this round of expectation repricing can be traced back to the unexpected rise in August wholesale price data. August U.S. PPI climbed to 5.4% year over year, up from 4.8% in July and far above the FED’s 2% inflation target. Core PPI rose 0.2% month over month, slightly below the market expectation of 0.3%, but its year-over-year g
BTC+1.22%
BZ-1.18%
GateInstantTrends·09-11 04:02
What is the probability that the Fed will raise interest rates at its Sept. meeting? From PPI to CPI, how are event markets pricing it?

Li Ka-shing-backed HUTCHMED stock jumps 40% after HUTCHMED licenses HMPL-A830 to GSK for preclinical development

Li Ka-shing's HUTCHMED subsidiary Hutchison Whampoa Pharmaceutical (Shanghai) announced that it had entered into an exclusive development and licensing agreement for HMPL-A830 with a subsidiary of British pharmaceutical company GlaxoSmithKline (GSK), granting the subsidiary worldwide development and commercialization rights outside China. The potential total value of the deal is up to $1.295 billion. As of Sept. 11, HUTCHMED shares had risen approximately 40% cumulatively from this year's June l
GSK-1.21%
Bisc·09-11 03:54
和黃醫藥HMPL-A830臨床前授權GSK